Welcome to our dedicated page for Envveno Medical news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical stock.
enVVeno Medical Corporation develops bioprosthetic venous valve devices for severe deep chronic venous insufficiency in the United States. News about NVNO centers on the company’s enVVe System, a minimally invasive transcatheter replacement venous valve, and its TAVVE pivotal study under FDA investigational device exemption approval.
Recurring updates also cover the VenoValve surgical replacement venous valve, FDA communications tied to device review, clinical-development planning, cash runway and operating losses, Nasdaq listing compliance, shareholder-approved capital-structure actions such as the reverse stock split, and investor communications from this late clinical-stage medical device issuer.
enVVeno Medical Corporation (NASDAQ:NVNO) reported its third-quarter 2022 financial results, ending with $42.7 million in cash and investments, providing a runway through 2024. The burn rate was $4.5 million for the quarter. Notably, the company is advancing its SAVVE pivotal trial with strong enrollment and is set to begin the TAVVE first-in-human study in early 2023. However, net losses increased to $6.1 million, up 154% year-over-year, primarily due to higher operating expenses, including a 140% rise in SG&A costs.
enVVeno Medical Corporation (NASDAQ:NVNO) announced CEO Rob Berman will participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, in New York, NY. Investors can join one-on-one meetings with management. A live video webcast will be available on the Company's website for 90 days post-event. enVVeno specializes in innovative solutions for venous disease, with its lead product, the VenoValve, in pivotal studies and awaiting approval for a non-surgical alternative, enVVe.
enVVeno Medical Corporation (NASDAQ: NVNO) will host a conference call and live audio webcast on September 21, 2022, at 4:30 PM ET. Interested parties can join by calling (877) 407-9708 (domestic) or (201) 689-8259 (international) using conference ID: 13732870. The live webcast will be available on the enVVeno website and archived for 90 days. The company focuses on innovative bioprosthetic solutions for venous disease, with its lead product, the VenoValve, currently in evaluation for treating Chronic Venous Insufficiency.
enVVeno Medical Corporation (Nasdaq: NVNO) announced CEO Robert Berman's participation at the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022. The event will include virtual one-on-one meetings with investors. A video webcast of the presentation will be live from September 12 at 7:00 AM ET, with a replay available for 90 days on their website. enVVeno focuses on innovative solutions for venous disease, including its lead product, the VenoValve, which is currently evaluated in the SAVVE pivotal study.
enVVeno Medical Corporation (NASDAQ: NVNO) has appointed Kevin Belteau as Vice President of Clinical Operations. Belteau brings over 23 years of experience from Medtronic, where he managed clinical operations for significant studies. enVVeno expects to engage in multiple clinical trials to support the adoption of its VenoValve device, aimed at treating Chronic Venous Insufficiency (CVI). The VenoValve is currently under evaluation in the SAVVE U.S. pivotal trial for safety and effectiveness, addressing a condition affecting around 2.4 million U.S. individuals.
enVVeno Medical Corporation (NASDAQ: NVNO) reported its second quarter results for 2022, ending with $47.2 million in cash and investments, sufficient to fund operations through 2024. The company noted a cash burn of $4.0 million in the quarter, aligning with expectations. However, net losses rose to $7.1 million, a 197% increase due to higher operating expenses. The ongoing SAVVE pivotal trial aims to evaluate the VenoValve for treating Chronic Venous Insufficiency, targeting approximately 2.4 million affected individuals in the U.S.
enVVeno Medical Corporation has announced that the American Medical Association has issued a new CPT III code for the VenoValve, effective January 1, 2023. This code allows for reimbursement for its procedure to treat Chronic Venous Insufficiency (CVI) in the deep veins of the leg, addressing a significant unmet medical need affecting approximately 2.4 million patients in the U.S. The VenoValve is currently under evaluation in the SAVVE U.S. pivotal trial, aiming to restore proper blood flow and alleviate symptoms caused by CVI.
enVVeno Medical Corporation (Nasdaq: NVNO) reported Q1 2022 financial results, ending the quarter with $51.3 million in cash, expected to fund operations through 2024. Their pivotal SAVVE trial is now active with 20 enrolled sites aiming to conclude patient recruitment by Q1 2023 and provide primary data in H2 2023. Despite a 89% rise in net losses to $5.3 million, company plans include unveiling a second device for venous disease in mid-2022, reinforcing their commitment to addressing chronic venous insufficiency affecting approximately 2.4 million Americans.
enVVeno Medical Corporation announced the issuance of U.S. Patent No. 11,285,243 for the VenoValve, a potential first-in-class treatment for Chronic Venous Insufficiency (CVI). The VenoValve is currently under evaluation in the SAVVE U.S. pivotal trial across major hospitals, addressing a significant unmet medical need for the 2.4 million U.S. patients suffering from deep venous CVI. The patent covers the manufacturing method of the valve's tissue component, enhancing protection for enVVeno's leading product and representing a significant step in its patent strategy.
enVVeno Medical Corporation (NASDAQ: NVNO) announced a strong cash position of $55 million, expected to fund operations through the end of 2024. The company has completed 9 VenoValve surgeries and has 16 clinical sites active in its pivotal SAVVE trial. The VenoValve's long-term safety and efficacy data were presented at a prominent medical meeting, and the company has also received ISO 13485 certification, aiding its commercialization efforts. Despite reporting a net loss of $16.5 million for 2021, cash reserves allow for focused execution of clinical trials.